Longitudinal Study of Transcriptomic Changes Occurring over Six Weeks of CHOP Treatment in Canine Lymphoma Identifies Prognostic Subtypes

Abstract

Simple Summary The standard of care for canine lymphoma is the CHOP chemotherapy protocol. The majority of patients initially achieve remission but eventually relapse with a multi-drug-resistant phenotype. We identified two transcriptionally distinct groups of canine lymphoma with a significant difference in progression-free survival. We describe the transcriptional differences between the two groups and how their transcription profiles change over the course of six weeks of CHOP treatment. These results contribute to the understanding of how canine lymphoma tumor cell populations respond to CHOP therapy.